It’s only a matter of days and another coronavirus vaccine is being approved in the US.



[ad_1]

Portfolio Signature for Christmas too.

Key analysis and exclusive content under the tree. You can even give someone a last minute gift with a one-year subscription to Portfolio Signature. And if you buy an annual subscription for multiple friends, friends and family at the same time, you can also get a quantity discount. So in addition to being a useful holiday gift, it can even support the production of quality inexpensive content. Know more

The vaccine, developed by a US biotech company, “does not have a special safety concern that does not allow for an emergency permit to be issued,” the FDA experts wrote in their study, which will meet Thursday to decide on the permit.

According to a statement from Moderna Results from the last phase of clinical trials suggest that the vaccine protects against asymptomatic infections after the first dose.

The company said 38 members of the control group were infected with asymptomatic coronaviruses at the time of the second vaccination. This is almost three times that of the vaccinated group, where 14 asymptomatic positive cases were found.

If FDA experts approve Moderna’s vaccine, which is estimated to be 94.1 percent effective, after the vaccine developed by Pfizer / BioNTech, it will be included in the largest vaccination campaign in the history of the United States. United to date.

What else?

Gábor Kemenesi, a biologist and virus researcher, commented on the virus’s Facebook page: “This, like Pfizer’s vaccine, is an mRNA-based preparation.” He also recalled that “it has been shown to be extremely effective in completely preventing severe disease COVID-19 in the study group.”

Store easier, no need for freezer (-70 C – Pfizer), this is enough at -20 degrees. It can also be stored for a long time at a simple refrigerator temperature, further alleviating logistical challenges.

he pointed.

This is what the United States plans

US authorities plan to vaccinate about 20 million Americans by the end of December and 100 million by the end of March.

The United States has purchased a total of 200 million doses of the Moderna vaccine, half of which is expected to be marketed in the second quarter of 2021 alone. Washington has linked an additional 100 million doses of vaccine from a product jointly developed by the American pharmaceutical company Pfizer and the German biotechnology company BioNTech.

In the first phase, nurses and nursing home residents most at risk of infection are vaccinated.

Moderna’s licensing process follows Pfizer / BioNTech, which was licensed by the FDA last Friday.

In the United States, more than 300,000 people have died from Covid-19 disease caused by a coronavirus called SARS-CoV-2, according to a summary from Johns Hopkins University in Baltimore.

The records occur in the largest economy in the world, with more than 200,000 daily infections and 2,500 or even 3,000 deaths.

Top image: In the image released on November 16, 2020, the logo of the American biotech company Moderna at the entrance of one of the company’s buildings in Norwood, Massachusetts, on February 25, 2020. Moderna announced the November 16, 2020 that its coronavirus vaccine is 94.5 percent effective. Source: MTI / EPA / CJ Gunther



[ad_2]